Aspira Women’s Health has experienced a precipitous drop in revenue, declining over 91% from $9.15 million in 2023 to $0.343 million in 2025, driven by operational shifts and market pressures. Despite this, the company is harnessing its proprietary AI-enabled multivariate index assays and FDA-cleared diagnostics as competitive moats while expanding into the larger endometriosis diagnostic market. Financial challenges persist with constrained capital resources and negative operating cash flows, but management is improving operating efficiency and pursuing new commercial contracts to stabilize performance. Key milestones include broadening Medicaid access and advancing pipeline launches, with funding availability representing the critical risk factor for sustained operations.